1. Huey, D. J., Hu, J. C. & Athanasiou, K. A. Unlike bone, cartilage regeneration remains elusive. Science (New York) 338, 917–921. https://doi.org/10.1126/science.1222454 (2012).
2. Castro-Vinuelas, R. et al. Induced pluripotent stem cells for cartilage repair: Current status and future perspectives. Eur. Cell Mater. 36, 96–109. https://doi.org/10.22203/eCM.v036a08 (2018).
3. Chesterman, P. J. & Smith, A. U. Homotransplantation of articular cartilage and isolated chondrocytes. An experimental study in rabbits. J. Bone Joint Surg. Br. 50, 184–197 (1968).
4. Adkisson, H. D. et al. Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. Stem Cell Res. 4, 57–68. https://doi.org/10.1016/j.scr.2009.09.004 (2010).
5. Kimura, T., Yamashita, A., Ozono, K. & Tsumaki, N. Limited immunogenicity of human induced pluripotent stem cell-derived cartilages. Tissue Eng. Part A 22, 1367–1375. https://doi.org/10.1089/ten.TEA.2016.0189 (2016).
6. Erdmann, J. ISTO Technologies aims to rescue damaged joints. Chem. Biol. 18, 275–276. https://doi.org/10.1016/j.chemb iol.2011.03.003 (2011).
7. Farr, J., Tabet, S. K., Margerrison, E. & Cole, B. J. Clinical, radiographic, and histological outcomes after cartilage repair with par- ticulated juvenile articular cartilage: A 2-year prospective study. Am. J. Sports Med. 42, 1417–1425. https://doi.org/10.1177/03635 46514528671 (2014).
8. Tompkins, M. DeNovo NT allograft. Oper. Tech. Sports Med. 21, 82–89 (2013).
9. Adkisson, H. D. et al. The potential of human allogeneic juvenile chondrocytes for restoration of articular cartilage. Am. J. Sports Med. 38, 1324–1333. https://doi.org/10.1177/0363546510361950 (2010).
10. Kuroda, T., Yasuda, S. & Sato, Y. Tumorigenicity studies for human pluripotent stem cell-derived products. Biol. Pharm. Bull. 36, 189–192. https://doi.org/10.1248/bpb.b12-00970 (2013).
11. Ito, E. et al. Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application. Sci. Rep. 9, 1881. https://doi.org/10.1038/s41598-018-38325-5 (2019).
12. Kuroda, T. et al. Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells. PLoS ONE 7, e37342. https://doi.org/10.1371/journal.pone.0037342 (2012).
13. Kusakawa, S. et al. Characterization of in vivo tumorigenicity tests using severe immunodeficient NOD/Shi-scid IL2Rgamma(null) mice for detection of tumorigenic cellular impurities in human cell-processed therapeutic products. Regener. Therapy 1, 30–37. https://doi.org/10.1016/j.reth.2014.12.001 (2015).
14. Yamashita, A. et al. Generation of Scaffoldless hyaline cartilaginous tissue from human iPSCs. Stem Cell Rep. 4, 404–418. https:// doi.org/10.1016/j.stemcr.2015.01.016 (2015).
15. Yamashita, A. et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513, 507–511. https://doi.org/10.1038/ nature13775 (2014).
16. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636. https://doi.org/10.1016/0014- 4827(65)90211-9 (1965).
17. Hayflick, L. The cell biology of aging. Clin. Geriatr. Med. 1, 15–27 (1985).
18. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621. https://doi. org/10.1016/0014-4827(61)90192-6 (1961).
19. Hasebe-Takada, N. et al. Application of cell growth analysis to the quality assessment of human cell-processed therapeutic products as a testing method for immortalized cellular impurities. Regener. Therapy 5, 49–54. https://doi.org/10.1016/j.reth.2016.06.005 (2016).
20. Kono, K. et al. Characterization of the cell growth analysis for detection of immortal cellular impurities in human mesenchymal stem cells. Biologicals 43, 146–149. https://doi.org/10.1016/j.biologicals.2014.11.007 (2015).
21. European medicines Agency EMEA/724428/2009 assessment report for ChondroCelect., (2009).
22. Organization, W. H. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. World Health Organ. Tech. Rep. Ser. 978, 3 (2013).
23. Dixon, D., Heider, K. & Elwell, M. R. Incidence of nonneoplastic lesions in historical control male and female Fischer-344 rats from 90-day toxicity studies. Toxicol. Pathol. 23, 338–348. https://doi.org/10.1177/019262339502300310 (1995).
24. Dinse, G. E., Peddada, S. D., Harris, S. F. & Elmore, S. A. Comparison of NTP historical control tumor incidence rates in female Harlan sprague dawley and fischer 344/N rats. Toxicol. Pathol. 38, 765–775. https://doi.org/10.1177/0192623310373777 (2010).
25. Haseman, J. K., Hailey, J. R. & Morris, R. W. Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol. Pathol. 26, 428–441. https://doi.org/10.1177/0192623398 02600318 (1998).
26. Aigner, T. et al. Histopathology atlas of animal model systems—overview of guiding principles. Osteoarthritis Cartilage 18(Suppl 3), S2-6. https://doi.org/10.1016/j.joca.2010.07.013 (2010).
27. Unni, K. K. & Inwards, C. Y. Dahlin’s Bone Tumors 6th edn. (Lippincott Williams & Wilkins, Philadelphia, 2020).
28. 28Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat Meth 8, 409–412, https://www.natur e.com/nmeth/journal/v8/n5/abs/nmeth.1591.html#supplementary-information (2011).